Molecular Diagnosis of Prostate Cancer: PCA3 and TMPRSS2:ERG Gene Fusion
Open Access
- 31 March 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 187 (3), 795-801
- https://doi.org/10.1016/j.juro.2011.10.133
Abstract
Widespread prostate specific antigen screening together with the increase in the number of biopsy cores has led to increased prostate cancer incidence. Standard diagnostic tools still cannot unequivocally predict prostate cancer progression, which often results in a significant overtreatment rate. We present recent findings on PCA3 and TMPRSS:ERG fusion, and describe their clinical implications and performance. The PubMed® database was searched for reports on PCA3 (130 articles), TMPRSS:ERG and ETS fusion (180 publications) since 1999. In recent years advances in genetics and biotechnology have stimulated the development of noninvasive tests to detect prostate cancer. Serum and urine molecular biomarkers have been identified, of which PCA3 has already been introduced clinically. The identification of prostate cancer specific genomic aberrations, ie TMPRSS2:ERG gene fusion, might improve diagnosis and affect prostate cancer treatment. Although several recently developed markers are promising, often showing increased specificity for prostate cancer detection compared to that of prostate specific antigen, their clinical application is limited. The only 2 true prostate cancer specific biomarkers identified to date remain PCA3 and TMPRSS2:ERG gene fusion.Keywords
This publication has 47 references indexed in Scilit:
- PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocolsWorld Journal of Urology, 2010
- Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangementsNature Genetics, 2010
- Clinical Implications of TMPRSS2-ERG Gene Fusion Expression in Patients With Prostate Cancer Treated With Radical ProstatectomyJournal of Urology, 2010
- Quantitative Proteomic Profiling of Prostate Cancer Reveals a Role for miR-128 in Prostate CancerMolecular & Cellular Proteomics, 2010
- ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical PracticeEuropean Urology, 2009
- TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by ProstatectomyCancer Research, 2009
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionNature, 2009
- A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate CancerCancer Research, 2008
- Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancerOncogene, 2007
- The impact of translocations and gene fusions on cancer causationNature Reviews Cancer, 2007